[C:1]([N:5]1[CH:9]=[C:8]([C:10]2[N:15]=[C:14]([O:16][C@@H:17]([C@H:19]3[CH2:23][N:22]([C@@H](C4C=CC(OC)=CC=4)C)[C:21](=[O:34])[CH2:20]3)[CH3:18])[C:13]3[N:35]([CH:38]([F:40])[F:39])[CH:36]=[N:37][C:12]=3[CH:11]=2)[CH:7]=[N:6]1)([CH3:4])([CH3:3])[CH3:2]>C(O)(C(F)(F)F)=O>[C:1]([N:5]1[CH:9]=[C:8]([C:10]2[N:15]=[C:14]([O:16][C@@H:17]([C@H:19]3[CH2:23][NH:22][C:21](=[O:34])[CH2:20]3)[CH3:18])[C:13]3[N:35]([CH:38]([F:40])[F:39])[CH:36]=[N:37][C:12]=3[CH:11]=2)[CH:7]=[N:6]1)([CH3:2])([CH3:3])[CH3:4](R)-4-((R)-1-(6-(1-tert-butyl-1H-pyrazol-4-yl)-3-(difluoromethyl)-3H-imidazo[4,5-c]pyridin-4-yloxy)ethyl)-1-((R)-1-(4-methoxyphenyl)ethyl)pyrrolidin-2-one 2.34 (max. 0.107 mmol) was dissolved in TFA (2 mL) and heated to 60° C. with stirring. After 15 h, the red solution was concentrated in vacuo and diluted with EtOAc (20 mL) and 1:1 saturated aqueous NaHCO3: brine (20 mL). The phases were separated and the aqueous phase was extracted with EtOAc (20 mL). The combined organic phase was dried over Na2SO4, filtered, and concentrated onto silica gel. Purification by silica gel chromatography (40% to 100% acetone in hexanes) provided (R)-4-((R)-1-(6-(1-tert-butyl-1H-pyrazol-4-yl)-3-(difluoromethyl)-3H-imidazo[4,5-c]pyridin-4-yloxy)ethyl)pyrrolidin-2-one 3.03.
読み込み中…